You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Safety of A2A Adenosine Agonist for Treatment of Sepsis

    SBC: ADENOSINE THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): ATL146e is a synthetic small molecule developed by Adenosine Therapeutics, LLC (ATL) that acts as a selective agonist of the adenosine A2A receptor. ATL146e, sterile solution for intravenous (i.v.) bolus injection, is currently in Phase III of clinical development for use as a coronary vasodilator in pharmacodynamic stress imaging. ATL146e, when administered pa ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  2. Mucosal modified vaccinina Ankara-based plaque vaccines

    SBC: INVIRAGEN, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Plague has devastated human and animal populations throughout history. In recent years, it has caused severe epidemics in many parts of the world, resulting in human deaths and severe economic losses. In addition, Yersinia pestis, the cause of plague, could be a devastating bioweapon. An intentional release of 50 kg of Y. pestis over a city of 5 million people ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  3. Provoking anti-tumor immune responses with Fas ligand

    SBC: APOPLOGIC PHARMACEUTICALS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): We have shown that Fas ligand (FasL) gene therapy induces protective immune responses in rodent models. Yet, despite these unquestioned benefits to study mechanistic questions, various factors preclude precise extrapolation of safety data from rodent gene therapy studies to human trials. Hence, we have used spontaneous cancers of dogs as intermediaries for tran ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  4. Monitoring System For Vector-Based Influenza Vaccine

    SBC: INDEVR, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This Advanced Technology proposal is in response to NIAID's recently issued Notice of High-Priority Influenza Research Areas [NOT-AI-05-013]. In order to provide health officials with the tools required to efficiently combat a pandemic strain of influenza, it is essential that rapid and cost-effective methods for vaccine production be developed. Viral expressi ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  5. Microchips of Protein Kinase Substrates

    SBC: ATACTIC TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The long term goal of the proposed technology development is to take the current applications of the protein kinase (PK) substrate chips to the level suitable for proteome-scale applications and for developing clinical diagnostics. Recent years have witnessed dramatic expansion in our understanding of PK biology. In addition to the manifested intricate networks ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  6. Parallel DNA Assembling on MicroChip

    SBC: ATACTIC TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The increasing use of DNA as a molecular tool has ushered the technology of de novo synthesis of DNA back to the center stage of modern biology. We propose the development of a robust, ultra high-throughput (UHT) technology capable of genome-scale production of high fidelity synthetic DNA at about one percent of the cost and time of the current technologies. Ou ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  7. Label-Free NanOFET Microarrays with Embedded-Probe Nanocomposite Active Layers

    SBC: NANOHMICS INC            Topic: N/A

    DESCRIPTION (provided by applicant): Nanohmics, Inc. and Ambion, Inc. working in consortium with Dr. Susan Kauzlarich at the University of California Davis and Dr. Lynn Loo at the University of Texas at Austin propose to develop a Nanocomposite Organic Field-Effect Transistor (NanOFET) multiplex microarray platform for compact, label-free detection of oligonucleotide assays. The proposed method wi ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  8. MicroRNA Cellular Functions and Target Identification in Acute Myeloid Leukemia

    SBC: AMBION DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall objective for our proposed research is to use the emerging field of miRNA research to identify therapeutic targets for acute myeloid leukemia (AML), a genetically and phenotypically heterogeneous disorder of the hematopoietic stem cells that is characterized by failure of blood cells to differentiate and over- production of stem cells. The currently ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  9. FLOURESCENT TOOLS FOR THE STUDY OF METALLOTHIONEIN

    SBC: NEUROBIOTEX            Topic: N/A

    DESCRIPTION (provided by applicant): We will deliver to life scientists fluorescent tools for the study of metallothionein and metallothionein- zinc signaling. Metallothionein-zinc signals have recently emerged as central step in many life-or-death signal pathways, including proliferation, apoptosis and metastasis. Arguably, MT-zinc signaling rivals calcium-calmodulin, IP3, and nitric oxide in ubi ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  10. Oncogenic microRNAs in HPV-infected cervical samples

    SBC: AMBION DIAGNOSTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Cervical cancer, caused by human papillomaviruses (HPVs), is a major public health problem, worldwide. About 230,000 women die of cervical cancer every year, the majority in developing countries. Although early detection via routine cytological screenings (Pap smears) and HPV testing have lowered both the incidence and mortality of cervical cancer, significant ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government